- Home
- CEPU vs MNKD Comparison
CEPU vs MNKD Comparison
Compare CEPU & MNKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CEPU
- MNKD
- Stock Information
- Founded
- CEPU 1989
- MNKD 1991
- Country
- CEPU Argentina
- MNKD United States
- Employees
- CEPU N/A
- MNKD N/A
- Industry
- CEPU Electric Utilities: Central
- MNKD Biotechnology: Pharmaceutical Preparations
- Sector
- CEPU Utilities
- MNKD Health Care
- Exchange
- CEPU Nasdaq
- MNKD Nasdaq
- Market Cap
- CEPU 1.6B
- MNKD 1.7B
- IPO Year
- CEPU 2018
- MNKD 2004
- Fundamental
- Price
- CEPU $9.92
- MNKD $5.23
- Analyst Decision
- CEPU
- MNKD Strong Buy
- Analyst Count
- CEPU 0
- MNKD 5
- Target Price
- CEPU N/A
- MNKD $10.80
- AVG Volume (30 Days)
- CEPU 523.9K
- MNKD 4.5M
- Earning Date
- CEPU 11-07-2025
- MNKD 11-06-2025
- Dividend Yield
- CEPU 3.13%
- MNKD N/A
- EPS Growth
- CEPU N/A
- MNKD 149.32
- EPS
- CEPU 0.12
- MNKD 0.11
- Revenue
- CEPU $628,806,380.00
- MNKD $301,736,000.00
- Revenue This Year
- CEPU $11.09
- MNKD $16.36
- Revenue Next Year
- CEPU $10.25
- MNKD $20.34
- P/E Ratio
- CEPU $9.99
- MNKD $48.20
- Revenue Growth
- CEPU N/A
- MNKD 21.48
- 52 Week Low
- CEPU $7.43
- MNKD $3.38
- 52 Week High
- CEPU $16.60
- MNKD $7.63
- Technical
- Relative Strength Index (RSI)
- CEPU 57.66
- MNKD 49.05
- Support Level
- CEPU $7.60
- MNKD $4.79
- Resistance Level
- CEPU $8.09
- MNKD $5.90
- Average True Range (ATR)
- CEPU 0.67
- MNKD 0.26
- MACD
- CEPU 0.29
- MNKD -0.09
- Stochastic Oscillator
- CEPU 82.66
- MNKD 37.56
About CEPU Central Puerto S.A. (each represents ten)
Central Puerto SA is a power generation company. It is mainly engaged in electric power generation and commercialization. The company is also involved in the natural gas distribution public sector service in the Cuyo and Centro regions in Argentina. The Group has four reporting segments which includes electric power generation from conventional sources, electric power generation from renewable sources, natural gas transport and distribution, and forest activity.. The company derives maximum revenue from Electric Power Generation from conventional sources segment.
About MNKD MannKind Corporation
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.